SG11201407613RA - Process for making hydroxylated cyclopentylpyrimidine compounds - Google Patents
Process for making hydroxylated cyclopentylpyrimidine compoundsInfo
- Publication number
- SG11201407613RA SG11201407613RA SG11201407613RA SG11201407613RA SG11201407613RA SG 11201407613R A SG11201407613R A SG 11201407613RA SG 11201407613R A SG11201407613R A SG 11201407613RA SG 11201407613R A SG11201407613R A SG 11201407613RA SG 11201407613R A SG11201407613R A SG 11201407613RA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- boulder
- colorado
- array biopharma
- walnut street
- Prior art date
Links
- KHXLVDUXFUNEQQ-UHFFFAOYSA-N 2-cyclopentylpyrimidine Chemical class C1CCCC1C1=NC=CC=N1 KHXLVDUXFUNEQQ-UHFFFAOYSA-N 0.000 title abstract 3
- 241000758789 Juglans Species 0.000 abstract 2
- 235000009496 Juglans regia Nutrition 0.000 abstract 2
- 235000020234 walnut Nutrition 0.000 abstract 2
- GRZXWCHAXNAUHY-NSISKUIASA-N (2S)-2-(4-chlorophenyl)-1-[4-[(5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl]-1-piperazinyl]-3-(propan-2-ylamino)-1-propanone Chemical compound C1([C@H](C(=O)N2CCN(CC2)C=2C=3[C@H](C)C[C@@H](O)C=3N=CN=2)CNC(C)C)=CC=C(Cl)C=C1 GRZXWCHAXNAUHY-NSISKUIASA-N 0.000 abstract 1
- LTFBFZBWUKWXID-UHFFFAOYSA-N 1h-cyclopenta[d]pyrimidine Chemical class N1=CNC2=CC=CC2=C1 LTFBFZBWUKWXID-UHFFFAOYSA-N 0.000 abstract 1
- 101000582929 Homo sapiens Plasmolipin Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102100030265 Plasmolipin Human genes 0.000 abstract 1
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000003909 protein kinase inhibitor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/30—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261648421P | 2012-05-17 | 2012-05-17 | |
| US201361785281P | 2013-03-14 | 2013-03-14 | |
| PCT/US2013/041624 WO2013173736A1 (en) | 2012-05-17 | 2013-05-17 | Process for making hydroxylated cyclopentylpyrimidine compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201407613RA true SG11201407613RA (en) | 2015-01-29 |
Family
ID=48534507
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201407613RA SG11201407613RA (en) | 2012-05-17 | 2013-05-17 | Process for making hydroxylated cyclopentylpyrimidine compounds |
Country Status (18)
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2650511C2 (ru) | 2012-05-17 | 2018-04-16 | Дженентек, Инк. | Формы и составы пиримидинилциклопентанового соединения, композиции и способы, относящиеся к ним |
| AU2013262516B2 (en) | 2012-05-17 | 2017-10-19 | Genentech, Inc. | Process for making amino acid compounds |
| NZ702950A (en) | 2012-05-17 | 2016-09-30 | Genentech Inc | Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof |
| RU2643811C2 (ru) | 2012-05-17 | 2018-02-06 | Аррэй Байофарма Инк. | Способ получения гидроксилированных циклопентилпиримидиновых соединений |
| CA3207199A1 (en) | 2013-11-15 | 2015-05-21 | F. Hoffmann-La Roche Ag | Processes for the preparation of pyrimidinylcyclopentane compounds |
| WO2015078392A1 (en) * | 2013-11-27 | 2015-06-04 | Sunshine Lake Pharma Co., Ltd. | Processes for preparing dihydropyrimidine derivatives and intermediates thereof |
| CA2962901A1 (en) * | 2014-09-26 | 2016-03-31 | F.Hoffmann-La Roche Ag | Processes for preparing (cyclopentyl[d]pyrimidin-4-yl)piperazine compounds |
| CA3175354A1 (en) | 2020-06-16 | 2021-12-23 | F. Hoffmann-La Roche Ag | Process for making hydroxylated cyclopentylpyrimidine compounds |
| KR102689151B1 (ko) * | 2021-09-06 | 2024-07-29 | 연세대학교 산학협력단 | Akt 신호경로 억제제를 유효성분으로 포함하는 아토피피부염의 예방 또는 치료용 조성물 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU700579B2 (en) | 1993-12-12 | 1999-01-07 | Agrogene Ltd | A novel method to protect plants from fungal infection |
| EP0973396A4 (en) | 1997-04-07 | 2001-02-07 | Merck & Co Inc | METHOD FOR TREATING CANCER |
| US6201023B1 (en) | 1997-06-10 | 2001-03-13 | Agrogene Ltd. | Methods and compositions to protect crops against plant parasitic nematodes |
| EP0982300A3 (en) | 1998-07-29 | 2000-03-08 | Societe Civile Bioprojet | Non-imidazole alkylamines as histamine H3 - receptor ligands and their therapeutic applications |
| US6376496B1 (en) | 1999-03-03 | 2002-04-23 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| EP1188754B1 (en) | 1999-06-03 | 2005-06-01 | Teikoku Hormone Mfg. Co., Ltd. | Substituted pyrazole compounds |
| WO2001022963A1 (en) | 1999-09-27 | 2001-04-05 | Merck & Co., Inc. | Method of preventing osteoporosis |
| PE20050630A1 (es) | 2003-06-09 | 2005-09-22 | Boehringer Ingelheim Int | Compuestos heterociclicos como inhibidores del papiloma virus |
| CN1882347A (zh) | 2003-11-21 | 2006-12-20 | 阿雷生物药品公司 | Akt蛋白激酶抑制剂 |
| US8927546B2 (en) | 2006-02-28 | 2015-01-06 | Dart Neuroscience (Cayman) Ltd. | Therapeutic piperazines |
| US8063050B2 (en) * | 2006-07-06 | 2011-11-22 | Array Biopharma Inc. | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
| UA95641C2 (xx) * | 2006-07-06 | 2011-08-25 | Эррей Биофарма Инк. | Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы |
| JP5157576B2 (ja) | 2007-05-14 | 2013-03-06 | 住友化学株式会社 | 光学活性２−アルキル−１，１，３−トリアルコキシカルボニルプロパンの製造方法 |
| MX2009014013A (es) | 2007-07-05 | 2010-01-28 | Array Biopharma Inc | Pirimidil ciclopentanos como inhibidores de la proteina cinasa akt. |
| US20100298289A1 (en) | 2007-10-09 | 2010-11-25 | Ucb Pharma, S.A. | Heterobicyclic compounds as histamine h4-receptor antagonists |
| AU2009204025B2 (en) | 2008-01-09 | 2014-02-20 | Array Biopharma Inc. | Hydroxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
| MX2011003917A (es) * | 2008-10-15 | 2011-05-31 | Amgen Inc | Moduladores de grp40 espirociclicos. |
| CA2758484A1 (en) | 2009-04-15 | 2010-10-21 | David A. Degoey | Anti-viral compounds |
| MX2012004780A (es) | 2009-10-23 | 2012-08-23 | Lilly Co Eli | Inhibidores de akt. |
| US9050334B2 (en) | 2010-07-16 | 2015-06-09 | Innov88 Llc | MIF inhibitors and their uses |
| WO2012177925A1 (en) | 2011-06-21 | 2012-12-27 | The Board Institute, Inc. | Akt inhibitors for treating cancer expressing a magi3 - akt3 fusion gene |
| RU2643811C2 (ru) | 2012-05-17 | 2018-02-06 | Аррэй Байофарма Инк. | Способ получения гидроксилированных циклопентилпиримидиновых соединений |
| NZ702950A (en) | 2012-05-17 | 2016-09-30 | Genentech Inc | Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof |
| AU2013262516B2 (en) | 2012-05-17 | 2017-10-19 | Genentech, Inc. | Process for making amino acid compounds |
| CA2889855A1 (en) | 2012-11-01 | 2014-05-08 | Robert S. Katz | Methods for treating fibromyalgia |
| US20150376198A1 (en) | 2013-02-18 | 2015-12-31 | The Scripps Research Institute | Modulators of vasopressin receptors with therapeutic potential |
| CN105473141A (zh) | 2013-03-15 | 2016-04-06 | 实发生物医学公司 | 治疗和/或预防心血管疾病的抗pcsk9化合物和方法 |
-
2013
- 2013-05-17 PL PL13725533.7T patent/PL2861583T3/pl unknown
- 2013-05-17 JP JP2015512890A patent/JP6214636B2/ja active Active
- 2013-05-17 AU AU2013262568A patent/AU2013262568B2/en not_active Ceased
- 2013-05-17 WO PCT/US2013/041624 patent/WO2013173736A1/en active Application Filing
- 2013-05-17 MX MX2014013865A patent/MX2014013865A/es unknown
- 2013-05-17 SI SI201330302A patent/SI2861583T1/sl unknown
- 2013-05-17 MA MA37649A patent/MA37649B1/fr unknown
- 2013-05-17 CN CN201380037994.8A patent/CN104487430B/zh active Active
- 2013-05-17 BR BR112014028570A patent/BR112014028570A2/pt not_active IP Right Cessation
- 2013-05-17 ES ES13725533.7T patent/ES2588878T3/es active Active
- 2013-05-17 RU RU2014151017A patent/RU2014151017A/ru not_active Application Discontinuation
- 2013-05-17 EP EP13725533.7A patent/EP2861583B1/en active Active
- 2013-05-17 DK DK13725533.7T patent/DK2861583T3/en active
- 2013-05-17 CA CA2873653A patent/CA2873653A1/en not_active Abandoned
- 2013-05-17 SG SG11201407613RA patent/SG11201407613RA/en unknown
- 2013-05-17 US US14/401,091 patent/US9309204B2/en active Active
- 2013-05-17 KR KR20147035262A patent/KR20150020211A/ko not_active Withdrawn
-
2014
- 2014-11-13 IL IL235714A patent/IL235714A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL235714A0 (en) | 2015-02-01 |
| US9309204B2 (en) | 2016-04-12 |
| PL2861583T3 (pl) | 2016-12-30 |
| HK1208673A1 (en) | 2016-03-11 |
| MX2014013865A (es) | 2015-05-07 |
| EP2861583B1 (en) | 2016-06-29 |
| ES2588878T3 (es) | 2016-11-07 |
| BR112014028570A2 (pt) | 2018-04-24 |
| CN104487430B (zh) | 2016-08-24 |
| KR20150020211A (ko) | 2015-02-25 |
| JP2015518837A (ja) | 2015-07-06 |
| RU2014151017A (ru) | 2016-07-10 |
| AU2013262568B2 (en) | 2017-08-31 |
| JP6214636B2 (ja) | 2017-10-18 |
| SI2861583T1 (sl) | 2016-10-28 |
| CA2873653A1 (en) | 2013-11-21 |
| EP2861583A1 (en) | 2015-04-22 |
| MA37649A1 (fr) | 2016-06-30 |
| DK2861583T3 (en) | 2016-10-03 |
| US20150099881A1 (en) | 2015-04-09 |
| CN104487430A (zh) | 2015-04-01 |
| AU2013262568A1 (en) | 2015-01-22 |
| MA37649B1 (fr) | 2017-03-31 |
| WO2013173736A1 (en) | 2013-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201407613RA (en) | Process for making hydroxylated cyclopentylpyrimidine compounds | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201804152RA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
| SG11201407591PA (en) | Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof | |
| SG11201807834WA (en) | Bridged bicyclic inhibitors of menin-mll and methods of use | |
| SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
| SG11201909278SA (en) | Fungicidal oxadiazoles | |
| SG11201810983PA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
| SG11201804098TA (en) | Purinones as ubiquitin-specific protease 1 inhibitors | |
| SG11201907544VA (en) | Jak inhibitors containing a 4-membered heterocyclic amide | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201811414TA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201408067YA (en) | Crystalline forms of a bruton's tyrosine kinase inhibitor | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201500005SA (en) | Pyrimidine pyrazolyl derivatives | |
| SG11201808878UA (en) | Heterocyclic compounds as ret kinase inhibitors | |
| SG11201407486PA (en) | Compositions and methods for modulating utrn expression | |
| SG11201408186TA (en) | Pyridinone and pyridazinone derivatives | |
| SG11201804934PA (en) | Novel Compounds | |
| SG11201408271VA (en) | Substituted pyrrolidines as factor xia inhibitors for the treatment thromboembolic diseases | |
| SG11201403402VA (en) | Compounds | |
| SG11201407793TA (en) | Compounds and compositions for modulating egfr activity | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases |